Published in Mol Cell on July 25, 2008
Protein arginine methylation in mammals: who, what, and why. Mol Cell (2009) 7.44
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Protein arginine methyltransferases and cancer. Nat Rev Cancer (2012) 2.56
Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol (2009) 1.95
Plasma membrane estrogen receptors. Trends Endocrinol Metab (2009) 1.85
G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression. Nat Commun (2016) 1.43
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol Cell Biol (2009) 1.40
Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem (2008) 1.37
Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol (2010) 1.29
Rapid signaling by steroid receptors. Am J Physiol Regul Integr Comp Physiol (2008) 1.18
Ctr9, a key subunit of PAFc, affects global estrogen signaling and drives ERα-positive breast tumorigenesis. Genes Dev (2015) 1.14
Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem (2011) 1.13
Thrombospondin-1 is a transcriptional repression target of PRMT6. J Biol Chem (2009) 1.12
The histone modifications governing TFF1 transcription mediated by estrogen receptor. J Biol Chem (2011) 1.10
Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One (2011) 1.06
Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci U S A (2013) 1.05
Kinase consensus sequences: a breeding ground for crosstalk. ACS Chem Biol (2011) 1.04
Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev (2012) 1.01
Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle (2013) 1.00
Insights into rapid modulation of neuroplasticity by brain estrogens. Pharmacol Rev (2013) 0.99
Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev (2015) 0.99
Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol (2014) 0.97
Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6). J Biol Chem (2012) 0.95
Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol (2013) 0.95
Minireview: role of protein methylation and demethylation in nuclear hormone signaling. Mol Endocrinol (2009) 0.95
Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation. Biosci Rep (2009) 0.95
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS One (2010) 0.94
Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics (2013) 0.94
JMJD6 regulates ERα methylation on arginine. PLoS One (2014) 0.94
Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry (2011) 0.93
Friend of Prmt1, a novel chromatin target of protein arginine methyltransferases. Mol Cell Biol (2010) 0.92
A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem (2010) 0.91
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol (2011) 0.91
Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med (2012) 0.91
Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle (2012) 0.89
Small Molecule Inhibitors of Protein Arginine Methyltransferases. Expert Opin Investig Drugs (2016) 0.89
Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol (2011) 0.88
Protein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cells. J Biol Chem (2010) 0.88
Arginine methylation-dependent regulation of ASK1 signaling by PRMT1. Cell Death Differ (2011) 0.87
Dynamic Arginine Methylation of Tumor Necrosis Factor (TNF) Receptor-associated Factor 6 Regulates Toll-like Receptor Signaling. J Biol Chem (2015) 0.86
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest (2015) 0.86
Emerging technologies to map the protein methylome. J Mol Biol (2014) 0.86
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget (2015) 0.86
Retracted Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci (2014) 0.84
Transmethylation in immunity and autoimmunity. Clin Immunol (2011) 0.84
Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest. Mol Cell Proteomics (2014) 0.83
Post-ischemic estradiol treatment reduced glial response and triggers distinct cortical and hippocampal signaling in a rat model of cerebral ischemia. J Neuroinflammation (2012) 0.83
Point mutations in the ERα Gαi binding domain segregate nonnuclear from nuclear receptor function. Mol Endocrinol (2012) 0.82
Unliganded estrogen receptor alpha promotes PC12 survival during serum starvation. PLoS One (2013) 0.82
Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells. Mol Endocrinol (2013) 0.82
Estrogen amelioration of Aβ-induced defects in mitochondria is mediated by mitochondrial signaling pathway involving ERβ, AKAP and Drp1. Brain Res (2015) 0.81
Extranuclear signaling by estrogen: role in breast cancer progression and metastasis. Minerva Ginecol (2010) 0.81
Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci (2015) 0.81
Protein Arginine Methylation and Citrullination in Epigenetic Regulation. ACS Chem Biol (2015) 0.81
Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Mol Oncol (2016) 0.81
The Expanding Complexity of Estrogen Receptor Signaling in the Cardiovascular System. Circ Res (2016) 0.81
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes. Mol Biol Cell (2013) 0.80
Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J Biol Chem (2014) 0.80
Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1. PLoS One (2013) 0.80
Role of JMJD6 in Breast Tumourigenesis. PLoS One (2015) 0.80
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. J Mol Endocrinol (2015) 0.79
A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells. J Biol Chem (2014) 0.78
Protein arginine methyltransferase 1 interacts with and activates p38α to facilitate erythroid differentiation. PLoS One (2013) 0.77
Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal (2010) 0.77
The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Clin Epigenetics (2016) 0.76
Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol (2010) 0.76
The Role of Protein Arginine Methyltransferases in Inflammatory Responses. Mediators Inflamm (2016) 0.76
Lysine methylation of progesterone receptor at activation function 1 regulates both ligand-independent activity and ligand sensitivity of the receptor. J Biol Chem (2014) 0.75
The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. Sci Rep (2016) 0.75
Protein arginine methylation/demethylation and cancer. Oncotarget (2016) 0.75
The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer. Oncogene (2016) 0.75
Arginine methylation: making its mark on AP-1 gene activation. Cell Cycle (2013) 0.75
Protective Hematopoietic Effect of Estrogens in a Mouse Model of Thrombosis: Respective Roles of Nuclear Versus Membrane Estrogen Receptor α. Endocrinology (2015) 0.75
Single nucleotide polymorphisms in the FcγR3A and TAP1 genes impact ADCC in cynomolgus monkey PBMCs. Immunogenetics (2017) 0.75
Protein arginine methylation: a prominent modification and its demethylation. Cell Mol Life Sci (2017) 0.75
Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells. Sci Rep (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A (2008) 1.95
Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol (2005) 1.70
Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell (2013) 1.68
Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene (2002) 1.65
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol (2002) 1.46
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev (2011) 1.39
Conservation of the deadenylase activity of proteins of the Caf1 family in human. RNA (2005) 1.38
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res (2011) 1.24
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res (2011) 1.23
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res (2012) 1.22
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res (2012) 1.16
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer (2009) 1.11
Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res (2013) 1.11
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
BTG2 antiproliferative protein interacts with the human CCR4 complex existing in vivo in three cell-cycle-regulated forms. J Cell Sci (2003) 1.07
hCAF1, a new regulator of PRMT1-dependent arginine methylation. J Cell Sci (2007) 1.07
CD208/dendritic cell-lysosomal associated membrane protein is a marker of normal and transformed type II pneumocytes. Am J Pathol (2004) 1.06
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat (2011) 1.04
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat (2006) 1.03
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res (2007) 1.02
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol (2008) 1.00
Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer (2004) 1.00
Maternal Tgif is required for vascularization of the embryonic placenta. Dev Biol (2008) 0.98
Generation of mice with conditionally activated transforming growth factor beta signaling through the TbetaRI/ALK5 receptor. Genesis (2008) 0.98
Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene (2002) 0.97
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol (2010) 0.94
High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands. J Pathol (2013) 0.92
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol (2012) 0.91
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology (2012) 0.91
Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med (2012) 0.91
Protein arginine methylation in estrogen signaling and estrogen-related cancers. Trends Endocrinol Metab (2009) 0.90
Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. Am J Pathol (2012) 0.89
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res (2010) 0.89
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer (2014) 0.89
Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer (2011) 0.88
LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer. Int J Cancer (2014) 0.88
Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-β. J Cell Biol (2014) 0.86
Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol (2004) 0.84
Is surgical biopsy mandatory in case of atypical ductal hyperplasia on 11-gauge core needle biopsy? A retrospective study of 300 patients. Am J Surg (2008) 0.84
Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2012) 0.84
ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. PLoS One (2009) 0.84
Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene (2007) 0.84
hCAF1/CNOT7 regulates interferon signalling by targeting STAT1. EMBO J (2013) 0.83
Macrophage differentiation of myeloid progenitor cells in response to M-CSF is regulated by the dual-specificity phosphatase DUSP5. J Leukoc Biol (2009) 0.83
Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization. Bull Cancer (2012) 0.83
Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer (2013) 0.83
Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer (2014) 0.83
Magnetoresistance and magnetic ordering fingerprints in hydrogenated graphene. Phys Rev Lett (2011) 0.82
Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells. Mol Endocrinol (2013) 0.82
Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. EMBO Mol Med (2013) 0.81
Novel roles of the CCR4-NOT complex. Wiley Interdiscip Rev RNA (2014) 0.81
[Breast carcinoma with predominant neuroendocrine differentiation]. Ann Pathol (2004) 0.81
TIF1γ requires sumoylation to exert its repressive activity on TGFβ signaling. J Cell Sci (2013) 0.80
Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care (2006) 0.80
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat (2015) 0.79
Proximity ligation assay to detect and localize the interactions of ERα with PI3-K and Src in breast cancer cells and tumor samples. Methods Mol Biol (2014) 0.78
Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors. J Proteomics (2012) 0.77
Ligand-centered redox activity in cobalt(II) and nickel(II) bis(phenolate)-dipyrrin complexes. Chemistry (2012) 0.77
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 0.77
Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol (2010) 0.76
The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions. Pancreatology (2013) 0.76
New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res (2010) 0.75
Primary ovarian borderline tumor in the inguinal lymph node. Int J Gynecol Pathol (2013) 0.75
[Antihormonal therapy in breast cancer and mTOR inhibitors]. Bull Cancer (2011) 0.75
A singlet ground state for a cobalt(II)-anilinosalen radical complex. Chem Commun (Camb) (2014) 0.75
First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bull Cancer (2012) 0.75
[Post-translational modifications modulate estrogen receptor alpha activity in breast tumors]. Med Sci (Paris) (2010) 0.75
Synthesis and grafting of a BTP derivative onto a quartz crystal microbalance for lanthanide detection. Phys Chem Chem Phys (2010) 0.75
Mechanisms of resistance to endocrine therapies for breast cancer. Horm Mol Biol Clin Investig (2012) 0.75
[Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node]. Bull Cancer (2012) 0.75
[Neoadjuvant chemotherapy and ovarian cancer]. Bull Cancer (2006) 0.75
Distinct actions of strontium on mineral formation in matrix vesicles. Biochem Biophys Res Commun (2008) 0.75